# Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men

> **NCT02943239** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 82 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** REGN1033
- **DRUG:** REGN2477
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02943239
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-08
- **Primary completion:** 2019-04-30
- **Final completion:** 2019-04-30
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02943239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02943239, "Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02943239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*